Teva price target raised to $25 from $22 at Barclays

Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales potential of $1B-plus.